{"nctId":"NCT01598090","briefTitle":"Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir","startDateStruct":{"date":"2012-06-14","type":"ACTUAL"},"conditions":["Hepatitis C Virus"],"count":881,"armGroups":[{"label":"Part A: Peginterferon Lambda-1a + RBV + TVR","type":"EXPERIMENTAL","interventionNames":["Biological: Peginterferon Lambda-1a","Drug: Ribavirin","Drug: Telaprevir"]},{"label":"Part B (Arm 1): Peginterferon Lambda-1a + RBV + TVR","type":"EXPERIMENTAL","interventionNames":["Biological: Peginterferon Lambda-1a","Drug: Ribavirin","Drug: Telaprevir"]},{"label":"Part B (Arm 2): Peginterferon Lambda-2a + RBV + TVR","type":"EXPERIMENTAL","interventionNames":["Biological: Peginterferon Alfa-2a","Drug: Ribavirin","Drug: Telaprevir"]}],"interventions":[{"name":"Peginterferon Lambda-1a","otherNames":[]},{"name":"Peginterferon Alfa-2a","otherNames":["Pegasys"]},{"name":"Ribavirin","otherNames":[]},{"name":"Telaprevir","otherNames":["Incivek"]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.\n\nInclusion Criteria:\n\n* Chronic hepatitis C genotype 1. GT-1b Capped at 50 % of naïve subjects\n* Naives to prior anti-HCV therapy \\[Interferon (IFN) and direct antiviral agent (DAA) based\\]\n* Relapsers (defined as subjects who had undetectable HCV ribonucleic acid (RNA) on prior treatment regimen of alfa-2a/RBV and Hepatitis C Virus (HCV) RNA \\> 25IU/mL after discontinuation of treatment). Capped at 20%\n* HCV RNA ≥ 100,000 IU/mL\n* Subjects with compensated cirrhosis can be enrolled and will be capped at approximately 10%\n* Seronegative for human immunodeficiency virus (HIV) and hepatitis B surface antigen (HBsAg)\n* Men or women, 18-70 years of age\n\nExclusion Criteria:\n\n* Chronic liver disease due to causes other than chronic HCV\n* Current or past evidence of decompensation\n* Conditions that preclude the use of Alfa/RBV/TVR per respective labels\n* Diagnosed or suspected hepatocellular carcinoma","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Extended Rapid Virologic Response (eRVR) - Part A","description":"eRVR was defined as Hepatitis C virus (HCV) RNA level below the lower limit of quantitation, target not detected at Weeks 4 and 12 of treatment. HCV RNA level was measured using the Roche COBAS® TaqMan HCV Test v.2.0 (lower limit of quantitation =25 IU/mL; limit of detection \\~ 10 IU/mL).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - Part B","description":"SVR12 was defined as Hepatitis C virus (HCV) RNA level below lower limit of quantitation, target detected or not detected at Week 12 of post-treatment follow-up. HCV RNA level was measured using the Roche COBAS® TaqMan HCV Test v.2.0 (lower limit of quantitation =25 IU/mL; limit of detection \\~ 10 IU/mL).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Drug Related AEs, Discontinuation Due to AEs, Dose Reductions and Death - Part A","description":"An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal product. An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or caused prolongation of existing hospitalization.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - Part A","description":"SVR12 was defined as Hepatitis C virus (HCV) RNA level below lower limit of quantitation (LLOQ), target detected or not detected at Week 12 of post-treatment follow-up. HCV RNA level was measured using the Roche COBAS® TaqMan HCV Test v.2.0 (LLOQ =25 IU/mL; limit of detection \\~ 10 IU/mL).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Sustained Virologic Response at Follow-Up Week 24 (SVR24) - Part A","description":"SVR24 was defined as Hepatitis C virus (HCV) RNA level below lower limit of quantitation (LLOQ), target detected or not detected at Week 24 of post-treatment follow-up. HCV RNA level was measured using the Roche COBAS® TaqMan HCV Test v.2.0 (LLOQ) =25 IU/mL; limit of detection \\~ 10 IU/mL). The analysis was performed using Modified Intent-to-Treat method defined as the proportions of participants meeting the response criteria in numerator and denominator based on all treated participants. The analysis was performed in all treated participants.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Treatment-Naïve Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - Part B","description":"SVR12 was defined as Hepatitis C virus (HCV) RNA level below lower limit of quantitation, target detected or not detected at Week 12 of post-treatment follow-up. HCV RNA level was measured using the Roche COBAS® TaqMan HCV Test v.2.0 (lower limit of quantitation =25 IU/mL; limit of detection \\~ 10 IU/mL).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.6","spread":null},{"groupId":"OG001","value":"81.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Treatment Emergent Cytopenic Abnormalities - Part B","description":"Cytopenic abnormalities included anemia defined as hemoglobin \\<10 grams/decilitre; neutropenia defined as Absolute neutrophil count (ANC) \\<750 cubic millimetre (mm\\^3); thrombocytopenia defined as platelets \\<50,000 mm\\^3.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"55.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Extended Rapid Virologic Response (eRVR) - Part B","description":"eRVR was defined as Hepatitis C virus (HCV) RNA level below the lower limit of quantitation, target not detected at Weeks 4 and 12 of treatment. HCV RNA level was measured using the Roche COBAS® TaqMan HCV Test v.2.0 (lower limit of quantitation =25 IU/mL; limit of detection \\~ 10 IU/mL).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"70.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-Treatment Flu-Like Symptoms And Musculoskeletal Symptoms- Part B","description":"Flu-like symptoms included pyrexia, chills, and pain. Musculoskeletal symptoms included arthralgia, myalgia, and back pain.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"36.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":null},{"groupId":"OG001","value":"30.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response at Follow- upWeek 24 (SVR24) - Part B","description":"SVR24 was defined as Hepatitis C virus (HCV) RNA level below lower limit of quantitation (LLOQ), target detected or not detected at Week 24 of post-treatment follow-up. HCV RNA level was measured using the Roche COBAS® TaqMan HCV Test v.2.0 (LLOQ) =25 IU/mL; limit of detection \\~ 10 IU/mL).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Rash","description":"All skin reactions involving rash or rash-like events that occurred on treatment were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"36.3","spread":null},{"groupId":"OG002","value":"38.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":27},"commonTop":["Pruritus","Nausea","Fatigue","Rash","Insomnia"]}}}